Real-world outcome with abiraterone low-dose plus prednisone in patients with mCRPC in a Brazilian Public Cancer Center.

Luis Eduardo Rosa Zucca,Joao Antonio Junior Neif,Daniel D‘Almeida Preto,Isadora Clarissa Cordeiro Dias,Hadson Silva Araujo,Flavio Mavignier Cárcano,OncoGU

Real-world outcome with abiraterone low-dose plus prednisone in patients with mCRPC in a Brazilian Public Cancer Center.

2020

Luis Eduardo Rosa Zucca
Joao Antonio Junior Neif
Daniel D‘Almeida Preto
Isadora Clarissa Cordeiro Dias
Hadson Silva Araujo
Flavio Mavignier Cárcano
OncoGU

e17563Background: Abiraterone acetate (AA) is a potent selective and irreversible inhibitor of CYP17 used as standard treatment for metastatic Castration Resistant Prostate Cancer (mCRPC). In the p...

Keywords:

low dose
Oncology
Physical therapy
Abiraterone
Cancer
in patient
Internal medicine
Medicine
Prednisone

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations